Marina Bury

970 total citations
15 papers, 677 citations indexed

About

Marina Bury is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Marina Bury has authored 15 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 3 papers in Pharmacology and 2 papers in Oncology. Recurrent topics in Marina Bury's work include RNA modifications and cancer (5 papers), Ubiquitin and proteasome pathways (4 papers) and DNA Repair Mechanisms (2 papers). Marina Bury is often cited by papers focused on RNA modifications and cancer (5 papers), Ubiquitin and proteasome pathways (4 papers) and DNA Repair Mechanisms (2 papers). Marina Bury collaborates with scholars based in Belgium, Canada and Italy. Marina Bury's co-authors include Benjamin Le Calvé, Gerardo Ferbeyre, Frédéric Lessard, Volker Blank, Róbert Kiss, Carine Michiels, Thomas Dal Maso, Antonio Evidente, Véronique Mégalizzi and Walter Berger and has published in prestigious journals such as Journal of Biological Chemistry, Nature Cell Biology and Cancer Research.

In The Last Decade

Marina Bury

15 papers receiving 671 citations

Peers

Countries citing papers authored by Marina Bury

Since Specialization

Citations

This map shows the geographic impact of Marina Bury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Bury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Bury more than expected).

Fields of papers citing papers by Marina Bury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Bury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Bury. The network helps show where Marina Bury may publish in the future.

Co-authorship network of co-authors of Marina Bury

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Bury. A scholar is included among the top collaborators of Marina Bury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Bury. Marina Bury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	ACAD10 and ACAD11 allow entry of 4-hydroxy fatty acids into β-oxidation 2024 ·Cellular and Molecular Life Sciences ·(unknown), (unknown), Marina Bury, (unknown), (unknown), Isabelle Gerin, Vincent Stroobant, (unknown), (unknown), (unknown), Didier Vertommen, Emile Van Schaftingen, Joseph P. Dewulf, Guido T. Bommer	4
2	SUZ domain–containing proteins have multiple effects on nonsense-mediated decay target transcripts 2023 ·Journal of Biological Chemistry ·(unknown), Marina Bury, (unknown), Isabelle Gerin, (unknown), (unknown), Laurent Gatto, Didier Vertommen, Guido T. Bommer	1
3	Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment 2022 ·Oncogene ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Marina Bury, Nicole Beauchemin, Koren K. Mann, Volker Blank	21
4	Senescence Induced by UVB in Keratinocytes Impairs Amino Acids Balance 2022 ·Journal of Investigative Dermatology ·(unknown), (unknown), (unknown), (unknown), (unknown), Anne-Catherine Wéra, (unknown), Antoine Fattaccioli, Sophie Burteau, Catherine Demazy, Maude Fransolet, (unknown), Nathalie Martin, (unknown), Gauthier Decanter, Nicolas Penel, Marina Bury, Olivier Pluquet, Marjan Garmyn, Florence Debacq‐Chainiaux	22
5	New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy 2021 ·Trends in Cell Biology ·Marina Bury, Benjamin Le Calvé, Gerardo Ferbeyre, Volker Blank, Frédéric Lessard	93
6	Transmembrane (TMEM) protein family members: Poorly characterized even if essential for the metastatic process 2019 ·Seminars in Cancer Biology ·(unknown), Thomas Dal Maso, (unknown), Marina Bury, Johan Wouters, Carine Michiels, Benjamin Le Calvé	90
7	NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor 2019 ·Cell Reports ·Marina Bury, Benjamin Le Calvé, Frédéric Lessard, Thomas Dal Maso, (unknown), Carine Michiels, Gerardo Ferbeyre, Volker Blank	69
8	Phosphoglycolate has profound metabolic effects but most likely no role in a metabolic DNA response in cancer cell lines 2019 ·Biochemical Journal ·Isabelle Gerin, Marina Bury, (unknown), (unknown), Emile Van Schaftingen, Guido T. Bommer	8
9	Senescence-associated ribosome biogenesis defects contributes to cell cycle arrest through the Rb pathway 2018 ·Nature Cell Biology ·Frédéric Lessard, Sebastian Igelmann, Christian Trahan, Geneviève Huot, Emmanuelle Saint‐Germain, Lian Mignacca, (unknown), Stéphane Lopes‐Paciencia, Benjamin Le Calvé, Marinieve Montero, Xavier Deschênes‐Simard, Marina Bury, Olga Moiseeva, Marie‐Camille Rowell, Cornelia E. Zorca, Daniel Zenklusen, Léa Brakier‐Gingras, Véronique Bourdeau, Marlene Oeffinger, Gerardo Ferbeyre	111
10	Abstract 2086: Role of the transcription factor NFE2L3 in TNFα signaling pathway in colorectal cancer 2015 ·Cancer Research ·Marina Bury, Volker Blank	2
11	Fusicoccin A, a Phytotoxic Carbotricyclic Diterpene Glucoside of Fungal Origin, Reduces Proliferation and Invasion of Glioblastoma Cells by Targeting Multiple Tyrosine Kinases 2013 ·Translational Oncology ·Marina Bury, Anna Andolfi, Bernard Rogister, Alessio Cimmino, Véronique Mégalizzi, Véronique Mathieu, Olivier Féron, Antonio Evidente, Róbert Kiss	27
12	Ophiobolin A, a sesterterpenoid fungal phytotoxin, displays higher in vitro growth-inhibitory effects in mammalian than in plant cells and displays in vivo antitumor activity 2013 ·International Journal of Oncology ·Marina Bury, Esther Novo‐Uzal, Anna Andolfi, Sara Cimini, Nathalie Wauthoz, Petra Heffeter, Benjamin Lallemand, Fabiana Avolio, Cédric Delporte, Alessio Cimmino, Jacques Dubois, Pierre Van Antwerpen, Maria Chiara Zonno, Maurizio Vurro, Yves Poumay, Walter Berger, Antonio Evidente, Laura De Gara, Róbert Kiss, Vittoria Locato	34
13	Ophiobolin A induces paraptosis-like cell death in human glioblastoma cells by decreasing BKCa channel activity 2013 ·Cell Death and Disease ·Marina Bury, Alban Girault, Véronique Mégalizzi, Sabine Spiegl‐Kreinecker, (unknown), Walter Berger, Antonio Evidente, Alexander Kornienko, (unknown), Christophe Vandier, Róbert Kiss	144
14	In vitro anticancer activity, toxicity and structure–activity relationships of phyllostictine A, a natural oxazatricycloalkenone produced by the fungus Phyllosticta cirsii 2011 ·Toxicology and Applied Pharmacology ·Benjamin Le Calvé, Benjamin Lallemand, Carmen E. Perrone, Gaëlle Lenglet, Sabine Depauw, Gwendoline Van Goietsenoven, Marina Bury, Maurizio Vurro, (unknown), Anna Andolfi, Maria Chiara Zonno, Véronique Mathieu, François Dufrasne, Pierre Van Antwerpen, Yves Poumay, Marie‐Hélène David‐Cordonnier, Antonio Evidente, Róbert Kiss	14
15	N-(2-{3-[3,5-Bis(trifluoromethyl)phenyl]ureido}ethyl)-glycyrrhetinamide (6b): A Novel Anticancer Glycyrrhetinic Acid Derivative that Targets the Proteasome and Displays Anti-Kinase Activity 2011 ·Journal of Medicinal Chemistry ·Benjamin Lallemand, (unknown), Marina Bury, Céline Bruyère, (unknown), (unknown), Cédric Delporte, Michel Gelbcke, Véronique Mathieu, Jacques Dubois, Martine Prévost, Ivan Jabin, Róbert Kiss	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact